Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FGFR2 |
Variant | positive |
Impact List | unknown |
Protein Effect | unknown |
Gene Variant Descriptions | FGFR2 positive indicates the presence of the FGFR2 gene, mRNA, and/or protein. |
Associated Drug Resistance | |
Category Variants Paths |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 positive | Advanced Solid Tumor | sensitive | Aprutumab ixadotin | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, sensitivity to Aprutumab ixadotin (BAY1187982) positively correlated with Fgfr2 expression level in a variety of cancer cell lines in culture, and in cell line or patient-derived xenograft models (PMID: 27543601). | 27543601 |
FGFR2 positive | stomach cancer | sensitive | Aprutumab ixadotin | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, Aprutumab ixadotin (BAY1187982) inhibited survival of gastric cancer cell lines with elevated Fgfr2 expression level in culture, and suppressed tumor growth in cell line or patient-derived xenograft models (PMID: 27543601). | 27543601 |
FGFR2 positive | breast cancer | sensitive | Aprutumab ixadotin | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, Aprutumab ixadotin (BAY1187982) inhibited survival of Fgfr2 positive breast cancer cell lines in culture, and suppressed tumor growth in both cell line and patient-derived xenograft models (PMID: 27543601). | 27543601 |
FGFR2 positive | breast cancer | predicted - sensitive | Rogaratinib | Case Reports/Case Series | Actionable | In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease in a patient with FGFR2-positive breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741). | detail... |
FGFR2 positive | triple-receptor negative breast cancer | sensitive | Alofanib | Preclinical - Cell culture | Actionable | In a preclinical study, Alofanib (RPT835) treatment led to inhibition of cell proliferation in triple-receptor negative breast cancer cell lines expressing FGFR2 in culture, and inhibited tumor growth in cell line xenograft models (PMID: 27136102). | 27136102 |
FGFR2 positive | ovarian cancer | predicted - sensitive | Alofanib | Preclinical - Cell culture | Actionable | In a preclinical study, Alofanib (RPT835) inhibited growth in an ovarian cancer cell line expressing FGFR2 in culture (PMID: 27136102). | 27136102 |